Navigation Links
Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 2011
Date:2/7/2011

ANAHEIM, Calif., Feb. 7, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release financial results for the fourth quarter and full year ended December 31, 2010 on Wednesday, February 23, 2011 after the close of the U.S. financial markets.  The Company will host a conference call and webcast on Wednesday, February 23, 2011 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the fourth quarter and full year 2010, as well as current corporate developments.  This date is a schedule change from the Company's previously announced expectation to report fourth quarter and year-end results on February 22, 2011 announced in the January 10, 2011 press release.  Conference call details:Date:

Wednesday, February 23, 2011Time:

4:30 p.m. ETDial-in (U.S.):

877-941-6010Dial-in (International):

480-629-9772Web cast:

www.questcor.comTo access an audio replay of the call:Replay (U.S.):

800-406-7325Replay (International):

303-590-3030Replay Passcode:

4408313About QuestcorQuestcor Pharmaceuticals, Inc. is a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from two indications: the treatment of acute exacerbations of multiple sclerosis in adults and the treatment of infantile spasms in children under two years of age.  Questcor is also implementing plans to commercialize Acthar for use in treating nephrotic syndrome, another on-label indication. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals Reports Strong Finish to 2010
2. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2011
3. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
4. Questcor to Present at the Maxim Group Growth Conference
5. Questcor Reports Third Quarter 2010 Results
6. Questcor to Present at the 21st Annual Oppenheimer Healthcare Conference
7. Questcor Teams With Child Neurology Foundation (CNF) to Fund Infantile Spasms Scientific Research
8. Questcor and Child Neurology Foundation Support the 2nd Annual Infantile Spasms (IS) Awareness Week
9. Questcor to Present at UBS Global Life Sciences Conference
10. Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors
11. Questcor Receives Notification of PDUFA Date Extension to September 11, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
(Date:5/24/2016)... , May 24, 2016 ... Markt gebracht, die es Ärzten erlaubt, ihre Expertise ... behandeln: MDLinking kombiniert Live Streaming mit einer Instant-Messaging-Funktion ... zu kommunizieren. Mediziner in Europa, Afrika, Asien und ... bereits für die Plattform registriert. Information ...
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und demonstriert ... in ‚ausgezeichneter plus guter , ...    ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... heute neue positive Daten von der MORA-Studie der ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... ... seen a significant spike in their clients' employee participation for their wellness initiatives. ... screening by implementing a high-deductible health plan with outcome-based deductible incentives. As a ...
(Date:5/25/2016)... Jersey (PRWEB) , ... May 25, 2016 , ... ... technology firm will be selling the device branded as Stern’s Real Time Monitoring ... geared to bedbugs to the hotel and motel industry, colleges for use in dormitories, ...
(Date:5/24/2016)... ... May 24, 2016 , ... PhishLine, the best-in-class, enterprise ... company as Vice President of Sales. Cifolelli’s primary responsibilities include management of ... the rapidly expanding field of organizational social engineering. , “We are delighted ...
(Date:5/24/2016)... ... ... Jericho Project has named LaToya Williams-Belfort to the position of Chief Development and Communications ... the nationally-acclaimed nonprofit, working closely with CEO Tori Lyon and the Board of Directors ... , “LaToya Williams-Belfort is joining Jericho at an exciting time of growth and ...
(Date:5/24/2016)... , ... May 24, 2016 , ... How to Write ... Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major ... human error will ever be totally eliminated, many human performance problems can be prevented. ...
Breaking Medicine News(10 mins):